Lophora has identified and patented a new class of proprietary ligands. The company’s lead compound, LPH-5, is a highly selective small-molecule agonist of the serotonin 5-HT_2A receptor with robust CNS exposure and demonstrated target engagement. In preclinical models, LPH-5 has shown activity at sub-perceptual (non-psychedelic) dose levels. LPH-5 has completed dosing in a Phase I clinical trial, with early read-outs indicating a favourable safety and tolerability profile, supporting its potential suitability for multiple-dosing paradigms.